KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Gains from Sales and Divestitures (2018 - 2020)

Aquestive Therapeutics (AQST) has 3 years of Gains from Sales and Divestitures data on record, last reported at $64000.0 in Q4 2020.

  • For Q4 2020, Gains from Sales and Divestitures fell 48.8% year-over-year to $64000.0; the TTM value through Dec 2020 reached $64000.0, down 48.8%, while the annual FY2020 figure was $64000.0, 48.8% down from the prior year.
  • Gains from Sales and Divestitures reached $64000.0 in Q4 2020 per AQST's latest filing, roughly flat from $64000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $125000.0 in Q4 2019 and bottomed at $29802.0 in Q3 2018.
  • Average Gains from Sales and Divestitures over 3 years is $61680.2, with a median of $60000.0 recorded in 2018.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 218.77% in 2019, then tumbled 48.8% in 2020.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $60000.0 in 2018, then surged by 108.33% to $125000.0 in 2019, then crashed by 48.8% to $64000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $64000.0 in Q4 2020, $64000.0 in Q3 2020, and $60000.0 in Q2 2020.